Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2004-10-12
pubmed:abstractText
Hydroxyurea (HU) is known to increase gamma-globin chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still unclear. The aim of this study was to monitor treatment of a large cohort of patients with beta-thalassemia major in order to establish the response to HU and the associated elements.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1592-8721
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1172-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15477200-Adolescent, pubmed-meshheading:15477200-Adult, pubmed-meshheading:15477200-Alleles, pubmed-meshheading:15477200-Blood Transfusion, pubmed-meshheading:15477200-Child, pubmed-meshheading:15477200-Combined Modality Therapy, pubmed-meshheading:15477200-DNA Mutational Analysis, pubmed-meshheading:15477200-Drug Resistance, pubmed-meshheading:15477200-Female, pubmed-meshheading:15477200-Fetal Hemoglobin, pubmed-meshheading:15477200-Genetic Heterogeneity, pubmed-meshheading:15477200-Globins, pubmed-meshheading:15477200-Haplotypes, pubmed-meshheading:15477200-Humans, pubmed-meshheading:15477200-Hydroxyurea, pubmed-meshheading:15477200-Iran, pubmed-meshheading:15477200-Male, pubmed-meshheading:15477200-Splenectomy, pubmed-meshheading:15477200-Treatment Outcome, pubmed-meshheading:15477200-beta-Thalassemia
pubmed:year
2004
pubmed:articleTitle
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
pubmed:affiliation
Thalassemia Medical Center, Medical Faculty, Bandar Abbas University, Iran.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Multicenter Study